Views & Analysis Nanomedicine: delivering on its promise? The nanomedicines market is worth billions. Tarun Pandotra reviews developments in the sector.
Views & Analysis Data: underpinning health R&D Big data initiatives positioning the UK as a desirable location for R&D.
News Ipsen' Bylvay fluffs its lines in biliary atresia trial Ipsen's IBAT inhibitor Bylvay has failed a trial in biliary atresia, a rare and serious liver disease that affects babies and has limited treatments.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
